shot-button
Subscription Subscription
Home > Mumbai > Mumbai News > Article > Mumbai Infant suffering from spinal muscular atrophy gets medicine

Mumbai: Infant suffering from spinal muscular atrophy gets medicine

Updated on: 27 February,2021 09:07 AM IST  |  Mumbai
PTI |

The infant was given the imported Zolgensma medicine in Hinduja Hospital and is likely to be discharged on Saturday

Mumbai: Infant suffering from spinal muscular atrophy gets medicine

Photo for representational purpose

Teera Kamat, a six-month-old suffering from a rare disease, on Friday was administered a medicine whose cost is estimated to be Rs 16 crore and for which the Centre had waived off import duty and GST, officials said.


The child suffers from Spinal Muscular Atrophy, also known as SMA Type-1, a rare condition in which a complete breakdown of nerve cells in her brain and spinal cord result in zero control over muscle movement.


The infant was given the imported Zolgensma medicine in Hinduja Hospital and is likely to be discharged on Saturday, they said.


Zolgensma will help replace the missing or non-working motor neuron with a new one, they added.

Her parents, Priyanka and Mihir Kamat, had made fund raising appeals on social media and had also appealed to the government for relief on import duty and GST.

This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever.

"Exciting news! Mid-day is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest news!" Click here!


Mid-Day Web Stories

Mid-Day Web Stories

This website uses cookie or similar technologies, to enhance your browsing experience and provide personalised recommendations. By continuing to use our website, you agree to our Privacy Policy and Cookie Policy. OK